The global stem cell therapy market is expected to grow at a CAGR of 36 percent between 2017 and 2021. Here are the 10 top stem cell companies on the NASDAQ.
Stem cell research and regenerative medicine are growing markets in the life sciences sector, and the top stem cell companies are working hard to make advances.
Stem cells are the building blocks of life, with special capabilities that are particularly important in both the early and later stages of a humans life cycle.
Human stem cells have the ability to develop into a variety of different cell types in the body, including organ-specific cells, as well as muscle tissue and bone marrow cells; they can even renew themselves.
As the US National Institutes of Health explains, In many tissues (stem cells) serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. That said, theres still a lot of lab work that needs to be done before stem cell products can be used as cell-based therapies or regenerative medicines.
BIS Research estimatesthat the global stem cell therapy market totaled US$755.4 million in 2018 and is projected to grow at a compound annual growth rate of 28 percent until 2029 to reach US$11 billion.
The reports authors attribute this growth to increased government and organizational funding for stem cell research and new drug discovery, alongside rising awareness and proven effectiveness of stem cell therapy products. In turn, more stem cell therapy products are expected to receive regulatory approval and be launched in the market by the top stem cell companies.
A report from Grand View Research is even more bullish, projecting that the global stem cell market will reach US$17.9 billion by 2027. The research firm sees the presence of a strong, diverse clinical pipeline accelerat(ing) revenue generation in the global market, with a focus on developing advanced therapeutics for diseases like Alzheimers and Parkinsons.
Here the Investing News Network profiles the 10 top stem cell companies listed on the NASDAQ. The stocks listed below are in order of market cap size from biggest to smallest, with all numbers and figures current as of August 17, 2020.
Market cap: US$1.61 billion
Sangamo Therapeutics is working on genomic therapies, particularly in areas with unmet medical needs.
The companys gene therapy pipeline includes one Phase 3 program being developed in partnership with Pfizer (NYSE:PFE) for hemophilia A; one Phase 1/2 program for fabry disease; and one program in the preclinical stage for phenylketonuria, a rare genetic disorder.
Sangamos ex vivo gene-edited cell therapy programs include eight in different stages of development, including: a Phase 1/2 beta-thalassemia clinical trial in partnership with Sanofi (NYSE:SNY); a Phase 1/2 clinical trial for sickle cell disease, also in partnership with Sanofi; a solid organ transplant, which has completed the preclinical stages; two preclinical-stage oncology programs in partnership with Kite Pharma, a subsidiary of Gilead Sciences (NASDAQ:GILD); and one preclinical-stage program each for inflammatory bowl disease and multiple sclerosis (MS).
The company also has one in vivo genome-editing Phase 1/2 program for mucopolysaccharidosis type 2 and seven preclinical-stage in vivo gene-regulation programs for various disorders.
Market cap: US$694.59 million
Top stem cell company Vericel bases its treatments on tissue collection from patients. Its two lead products are Carticel and Epicel. Carticel seeks to treat cartilage defects in the knee. Epicel is aimed at treating patients with burns greater than or equal to 30 percent of their total body surface area.
The company also has exclusive license rights for the commercialization of NexoBrid in North America for the treatment of severe thermal burns.
Market cap: US$479.69 million
Athersys is a biopharmaceutical company focused on its lead stem cell product candidate, the MultiStem, which is being developed to treat multiple diseases related to neurological, inflammatory and immune and cardiovascular conditions, among others.
The companys most advanced programs are for treating ischemic stroke, one of the leading debilitating diseases in the US, Europe, Japan and China. MultiStem for the treatment of ischemic stroke is being evaluated in a Phase 2/3 trial in Japan and is in a Phase 3 trial at sites in North America and Europe.
MultiStem for the treatment of hematopoietic stem cell transplantation and graft versus host disease, a condition that can occur following transplantation, is in a Phase 3 pivotal study under special protocol assessment by the US Food and Drug Administration (FDA). The program was awarded Orphan Drug status by the FDA and European Medicines Agency, and was fast-tracked by the FDA.
Market cap: US$418.38 million
In the companys pipeline is its NurOwn technology platform, consisting of a range of products to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), progressive MS, Huntingtons disease, Parkinsons disease and autism spectrum disorder.
The company currently has a Phase 3 trial for using autologous MSC-NTF cells to treat ALS in six sites in the US, and an ongoing Phase 2 trial for the treatment of progressive MS.
Market cap: US$359.7 million
Cellular Biomedicine Group, one of the top stem cell companies, is in the clinical stages of developing immunotherapies for cancers in addition to stem cell therapies for degenerative diseases.
In its stem cell therapy pipeline are two therapeutic candidates to treat knee osteoarthritis AlloJoin and ReJoin the former of which has been approved to advance into a Phase 2 clinical trial, and the latter of which has completed a Phase 2b clinical trial.
In mid-2020, the company entered into a definitive merger agreement with a newly formed consortium that may see the company go private.
Market cap: US$222.3 million
This clinical-stage biotherapy company develops cell therapy to treat inflammation, ischemia, radiation damage and more. Pluristem develops placenta-derived off-the-shelf products.
The company produces its cells in a one-of-a-kind 3D bioreactor that resembles the environment of the human body. The bioreactor can generate the cells on a mass scale.
Market cap: US$197.89 million
Gamida Cells cell therapies are intended to treat blood cancers and rare hematologic conditions. Its lead product candidate is omidubicel, which can potentially act as a stem cell transplant for patients with high-risk blood cancer or bone marrow failure disorders.
The drug is currently being evaluated in a Phase 3 clinical study in leukemia and lymphoma patients, in addition to a Phase 1 study in patients with aplastic anemia.
Market cap: US$55.94 million
This biopharmaceutical company is seeking to develop and commercialize new chemical entities with regenerative potential, as well as cellular therapies involving stem cell-derived blood, cartilage, heart and liver cells. This top stem cell company also owns the subsidiary VistaStem, which is focused on using human stem cell technology to make human health predictions.
Market cap: US$34.84 million
Caladrius Biosciences product lines includes cardiovascular and autoimmune disease treatments.
The company currently has three product candidates for treating cardiovascular diseases based off of its CD34+ cell therapy platform. The first, CLBS12, has received SAKIGAKE designation in Japan and is thus is eligible to treat critical limb ischemia in Japan. It has also received advanced medicinal product classification in Europe. The company is targeting Q4 2021 for commercialization.
CLBS16 has the potential to treat coronary microvascular dysfunction in the US and is targeted to enter a Phase 2b trial in H2 2020. CLBS14 is entering a Phase 3 clinical program for refractory disabling angina.
Caladrius is also leveraging its expertise to combat the deleterious impact of COVID-19 on the lungs. A Phase 2 trial for CLBS119 is slated to begin in the third quarter of 2020 with the goal of evaluating the safety and efficacy of CD34+ cells for the repair of damaged tissue in the lungs of COVID-19 patients who have suffered respiratory failure.
Market cap: US$30.11 million
ThermoGenesis Holdings develops and commercializes automated cell processing technologies geared towards cell and gene therapy. Its solutions target automated clinical biobanking, point-of-care applications and large-scale cell processing for CAR T-based immunotherapies.
The top stem cell companys CARTXpress platform streamlines how CAR T immunotherapies are manufactured.
This is an updated version of an article first published on the Investing News Network in 2017.
Dont forget to follow us @INN_LifeScience for real-time news updates!
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
Read more:
10 Top Stem Cell Companies on the NASDAQ | INN - Investing News Network
- 'Didn't know this would be possible': Autistic teen's mom on stem cell therapy benefits - WZTV - May 6th, 2024
- John Cleese says he's been spending 17,000 annually on stem cell therapy to 'buy a few extra years' - Yahoo News UK - April 24th, 2024
- Promethera Bets Liver-Derived Stem Cells Will Offer Benefits In NASH - Scrip - April 24th, 2024
- Stem Cell Therapies: Is This The Future Of Wellness? - Grazia USA - April 20th, 2024
- Signal of Benefit for Stem Cell Therapy in Progressive MS - Medscape - March 7th, 2024
- The Controversies Surrounding Stem Cell Therapy for Autism - The Portugal News - February 24th, 2024
- Benefits of Stem Cell Therapy - News Channel 5 Nashville - February 7th, 2024
- What is Stem Cell Therapy & How It Helps Others - Publicist Paper - January 31st, 2024
- A guide to stem cell therapy in Thailand - Thaiger - January 4th, 2024
- Half of pediatric patients with aHUS benefit from Soliris after... - AHUS News - December 21st, 2023
- Real world analysis on the determinants of survival in primary ... - Nature.com - December 5th, 2023
- The Best Beauty Gifts According To People Who Really Know Skin Care - HuffPost - December 5th, 2023
- The Eyepopping Factory Construction Boom in the US - WOLF STREET - December 3rd, 2023
- Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress ... - Targeted Oncology - December 1st, 2023
- Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy ... - Curetoday.com - December 1st, 2023
- Review What Real Cavityn Customers Say About Benefits and Side ... - Seattle Weekly - December 1st, 2023
- 'There is a Scientific Fraud Epidemic' - Slashdot - Slashdot - December 1st, 2023
- 15 Best Hydrating Serums to Soothe Any Skin Type 2023 - Town & Country - December 1st, 2023
- Innovations in Cosmetic Dermatology: A Glimpse into the Future - APN News - December 1st, 2023
- FDA Probes New Cases of Cancer That May Stem From Cancer Cell ... - MedCity News - November 29th, 2023
- Use of plant stem cells in topical formulations on the rise - CosmeticsDesign.com USA - November 29th, 2023
- Stem cell-based treatment controls blood sugar in people with Type ... - EurekAlert - November 29th, 2023
- Biologics Market is projected to grow at a CAGR of 8.5% by 2034: Visiongain - Yahoo Finance - November 29th, 2023
- Scientists devise new technique that can pinpoint the causes and ... - EurekAlert - November 29th, 2023
- Global Advanced Therapy Medicinal Products Market is on the brink ... - PharmiWeb.com - November 29th, 2023
- Introducing Orgavalue - The 2023 EIT InnoStars Awards winner - EU-Startups - November 29th, 2023
- Episode 160: Euan Ashley discusses precision medicine and the ... - IHMC - November 29th, 2023
- Is Phenq Right For You? Review The Facts Before Making a ... - Vashon-Maury Island Beachcomber - November 27th, 2023
- Cavityn Reviews - Does It Work? Cheap Scam or Effective ... - The Daily World - November 25th, 2023
- Trend Hunting With Beautystreams At Cosmoprof Asia 2023 - BeautyMatter - November 25th, 2023
- FDA Considers First CRISPR Gene Editing Treatment That May ... - Slashdot - November 25th, 2023
- How Do Plants Determine Where the Light Is Coming From? - Lab Manager Magazine - November 25th, 2023
- Deaths From Coal Pollution Have Dropped, But Emissions May be ... - Slashdot - November 25th, 2023
- Stem cell-based therapies for stroke in newborns - Cochrane - November 23rd, 2023
- Dr Leslie on Outpatient CAR T-Cell Therapy Programs for ... - OncLive - November 23rd, 2023
- Human Milk-Based Therapy May Be Beneficial in Blood Cancers - Curetoday.com - November 23rd, 2023
- Oncological Horizons: The Synergy of Medical and Surgical ... - Cureus - November 23rd, 2023
- Human and environmental safety of carbon nanotubes across their ... - Nature.com - November 23rd, 2023
- Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted ... - BioSpace - November 23rd, 2023
- #HearTheMarsdenKids call on NHS London to reconsider cancer ... - Metro.co.uk - November 23rd, 2023
- Diagnosis and Management of Cardiovascular Risk in Patients with ... - Dove Medical Press - November 23rd, 2023
- BioLineRx Reports Third Quarter 2023 Financial Results and ... - PR Newswire - November 21st, 2023
- Why our Award Winners Beauty Box is the ultimate beauty gift (for ... - Yahoo Singapore News - November 21st, 2023
- SightCare Reviews - Is Official Website for Sight Care Legit to Try or ... - Vashon-Maury Island Beachcomber - November 21st, 2023
- Legend Biotech Reports Third Quarter 2023 Results and Recent ... - StreetInsider.com - November 21st, 2023
- Lorenzo's Oil: Can It Really Treat ALD? - Verywell Health - November 19th, 2023
- Doctor Says Living To 120 By End Of Decade Is Possible What's the Secret? - Benzinga - November 19th, 2023
- The week in pharma: action, reaction and insight week to ... - The Pharma Letter - November 19th, 2023
- Race Cannot Be Used To Predict Heart Disease, Scientists Say ... - Slashdot - November 19th, 2023
- SpaceX's Starship Reaches Outer Space Before Intentional ... - Slashdot - November 19th, 2023
- Mesenchymal Stem Cells Market is projected to reach USD 3,319 million by 2030 according to a new research r... - WhaTech Technology and Markets News - November 17th, 2023
- LMRUK: Protecting the next generation through cord blood - Charity Today News - November 17th, 2023
- Anti-aging molecule discovered that extends lifespan - Earth.com - November 17th, 2023
- Montana State researcher envisions living building materials that ... - Montana State University - November 17th, 2023
- OxyHelp Explores the Benefits of Hyperbaric Oxygen Therapy for ... - StreetInsider.com - November 15th, 2023
- Health benefits of bone marrow - Pakistan Observer - November 15th, 2023
- Evolving the standard of care: What is next for functional ... - NeuroNews International - November 15th, 2023
- Affimed Reports Third Quarter 2023 Financial Results and ... - BioSpace - November 15th, 2023
- Meet the World's First Whole-Eye Transplant Recipient - TIME - November 15th, 2023
- Calidi Biotherapeutics Reports Third Quarter 2023 Operating and ... - Business Wire - November 15th, 2023
- 10 Asia-Pacific biotech companies leading innovation in the region - Labiotech.eu - November 15th, 2023
- Fitspresso Reviews (November Update) Natural Ingredients That ... - Bainbridge Island Review - November 15th, 2023
- 2seventy bio Reports Third Quarter Financial Results and Recent ... - Business Wire - November 15th, 2023
- Japan To Create $6.6 Billion Fund To Develop Outer Space Industry ... - Slashdot - November 15th, 2023
- Be The Match, Healthcare Marketing Impact Awards 2023 - Ad Age - November 13th, 2023
- Medicare coverage saves lives. Enrolling shouldn't be this ... - Kevin MD - November 13th, 2023
- Future Ocean Foods: 36 Global Alt-Seafood Startups Form Association To Tackle Overfishing, Microplastics & More - Green Queen Media - November 13th, 2023
- Orchard Therapeutics Reports Third Quarter 2023 Financial Results ... - StreetInsider.com - November 13th, 2023
- Celebrity doctor reveals Hollywoods hidden trend of stem cell antiaging therapies - Longevity.Technology - November 11th, 2023
- Amazon Expands Healthcare Push With One Medical Benefits For ... - Slashdot - November 11th, 2023
- Bene Meat Technologies becomes the first to receive EU approval ... - Pet Food Processing - November 11th, 2023
- FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma - Yahoo Finance - November 11th, 2023
- MaaT Pharma Provides Third Quarter 2023 Business Update and ... - Business Wire - November 11th, 2023
- IN8bio Reports Third Quarter 2023 Financial Results and Provides ... - GlobeNewswire - November 11th, 2023
- Fast Lean Pro Reviews - Overpriced or Optimal Ingredients That ... - Journal of the San Juan Islands - November 11th, 2023
- Fate Therapeutics Reports Third Quarter 2023 Financial Results and ... - GlobeNewswire - November 11th, 2023
- Worlds first whole-eye and partial face transplant gives Arkansas man new hope - CNN - November 9th, 2023
- Glowing Fingertips And Green Eyes: First-of-Its-Kind Monkey ... - ScienceAlert - November 9th, 2023
- 10 Natural Body Scrubs That Exfoliate And Invigorate My Skin - PINKVILLA - November 9th, 2023
- CRISPR Therapeutics Provides Business Update and Reports Third ... - StreetInsider.com - November 9th, 2023
Recent Comments